Revive Therapeutics closes first tranche of $2 million placement

Revive Therapeutics (RVV) has closed the first tranche of its private placement, raising $2 million. This financing is part of a larger offering that aims to support the development of its psilocybin-based therapies. With the funds generated, Revive plans to further its clinical trials and expand its research initiatives. The successful closure of this tranche highlights investor interest in the company’s innovative approach in the therapeutic space, which may influence market sentiment around similar biotech firms.